Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American academy of neurology

Neurology

Volumn 79, Issue 6, 2012, Pages 597-603

  Armstrong, Melissa J ^a   Miyasaki, Janis M ^b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CLOZAPINE; CREATINE; DONEPEZIL; ETHYL EICOSAPENTAENOIC ACID; MINOCYCLINE; NABILONE; PLACEBO; REMACEMIDE; RILUZOLE; TETRABENAZINE; UBIDECARENONE; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY FAILURE; AGITATION; AGRANULOCYTOSIS; ALLERGIC PNEUMONITIS; ANXIETY; ARTICLE; CARDIOVASCULAR EFFECT; CONFUSION; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FALLING; HALLUCINATION; HEART ARREST; HEPATITIS; HUMAN; HUNTINGTON CHOREA; INSOMNIA; INTERSTITIAL LUNG DISEASE; JAUNDICE; LUNG EDEMA; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PARKINSONISM; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW;

EID: 84866131013     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318263c443     Document Type: Article

References (31)

1. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 1986;36:244 -249.
2. Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 2003;74:120 -122.
3. Beglinger LJ, O'Rourke JF, Wang C, et al. Huntington Study Group Investigators. Earliest functional declines in Huntington disease. Psychiatry Res 2010;178:414-418.
4. Paulsen JS, Wang C, Duff K, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord 2010;25:2595-2603.
5. Mahant N, McCusker EA, Byth K, Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61:1085-1092.
6. Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 2010;6:657- 665.
7. Grimbergen YAM, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M. Falls and gait disturbances in Huntington's disease. Mov Disord 2008;23:970 -976.
8. Andre VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 2010;16:163-178.
9. Krobitsch S, Kazantsev AG. Huntington's disease: from molecular basis to therapeutic advances. Int J Biochem Cell Biol 2011;43:20 -24.
10. Kieburtz K. The Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136 -142.
11. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366 -372.
12. Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31:127-133.
13. Paulsen JS, Ferneyhough Hoth K, Nehl C, Stierman L. The Huntington Study Group. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry 2005;162: 725-731.
14. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study: Huntington Study Group/TETRA-HD Investigators. BMC Neurol 2009;9:62.
15. Van Vugt JPP, Siesling S, Vergeer M, van der Velde EA, Roos RAC. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63:3539.
16. O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60: 996-998.
17. Verhagen Metman L, Mooris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDAantagonist amantadine. Neurology 2002;59:694-699.
18. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003;61:1551-1556.
19. Landwehrmeyer GB, Dubois B, Garcia de Yébenes J, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62:262-272.
20. Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebocontrolled trial. Neurology 2005;65:286 -292.
21. Huntington Study Group Trend-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study [erratum in 2009;66:305]. Arch Neurol 2008;65:1582-1589.
22. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2-dG. Neurology 2006;66:250-252.
23. Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006;67:1268 -1271.
24. Huntington Study Group. A randomized, placebocontrolled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397- 404.
25. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 2004;63:547-549.
26. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009;24:2254 -2259.
27. Marder K, Zhao RH, Myers M, et al Huntington Study Group. Rate of functional decline in Huntington's disease. Neurology 2000;54:452- 458.
28. Priller J, Ecker D, Landwehrmeyer B, et al. A Europe-wide assessment of current medication choices in Huntington's disease. Mov Disord 2008;23:1788.
29. Roos RA, de Haas EJ, Buruma OJ, deWolff FA, et al. Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease. Eur J Clin Pharmacol 1986;31:191-194.
30. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984;9:329 -338.
31. Prescriber information: Xenazine (tetrabenazine). Deerfield, IL: Lundbeck Inc.; 2011.